{"id":"W4414379673","doi":"10.1093/oncolo/oyaf270","title":"Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"Genentech; Servier; European Society for Medical Oncology; Eisai; Verastem Oncology; Clovis Oncology; Astellas Pharma; Novocure; Regeneron Pharmaceuticals; Amgen; Mereo BioPharma; Pfizer; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Mersana Therapeutics; PTC Therapeutics; GlaxoSmithKline","keywords":"Clinical trial; Ovarian cancer; Immunotherapy; Bevacizumab; PARP inhibitor; Phases of clinical research; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003869711,0.0002940492,0.001365132,0.0001295232,0.0003180989,0.00002532662,0.0001364685,0.0002175354,0.0003644385],"category_scores_gemma":[0.00112649,0.0001893378,0.0005995742,0.000347658,0.0005842538,0.0000654452,0.00002315341,0.0001734695,0.000005362629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00144925,"about_ca_system_score_gemma":0.002016494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004670417,"about_ca_topic_score_gemma":0.000157277,"domain_scores_codex":[0.9964471,0.0007775794,0.001727471,0.0004320125,0.0002722177,0.0003436141],"domain_scores_gemma":[0.9945984,0.003453982,0.0009307582,0.0006426819,0.0002820501,0.00009216629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04050136,0.003477344,0.0002109396,0.0000971814,0.000850128,0.000008508394,0.000768655,0.000267368,0.08601316,0.0006101899,0.00307761,0.8641176],"study_design_scores_gemma":[0.4116598,0.04500175,0.001468994,0.001600683,0.002304196,0.00002645942,0.0009014685,0.007692534,0.3556773,0.005197164,0.167808,0.0006616418],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.854414,0.02883052,0.02273687,0.07556572,0.004516409,0.01028878,0.001060291,0.0002501991,0.002337187],"genre_scores_gemma":[0.9737952,0.006163277,0.003511276,0.004497297,0.002205184,0.003578049,0.0002203735,0.00005800442,0.005971382],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8634559,"threshold_uncertainty_score":0.7720972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2927783521745961,"score_gpt":0.5819201111673444,"score_spread":0.2891417589927484,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}